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Abstract
OBJECTIVE: To compare the impacts of electroacu-
puncture (EA) and moxibustion (Mox) on the prima-
ry gastrointestinal symptoms and the expressions
of colonic mucosa-associated neuropeptide sub-
stance P (SP) and vasoactive intestinal peptide (VIP)
in patients with either diarrhea-predominant or
constipation-predominant irritable bowel syn-
drome (IBS-D and IBS-C, respectively).
METHODS: Eighty-five IBS patients were randomly
allocated to the EA and Mox groups. Zusanli (ST 36)
and Shangjuxu (ST 37) were selected as acupoints
for electroacupuncture or warm moxibustion treat-
ment once a day for 14 consecutive days. Before
and after the treatment sessions, a Visual Analog
Pain Scale and the Bristol Stool Form Scale were
used to evaluate gastrointestinal symptoms. There
were four dropout cases, leaving 81 participants
(41 with IBS-D and 40 with IBS-C) who volunteered
to undergo colonoscopy before and after the treat-
ment sessions. During colonoscopy, sigmoid muco-
sa were collected to detect SP and VIP expression
using immunohistochemistry assay.
RESULTS: Both EA and Mox treatments were effec-
tive at relieving abdominal pain in IBS-D and IBS-C
patients. However, Mox was more effective at re-
ducing diarrhea in IBS-D patients, whereas EA was
more effective at improving constipation in IBS-C
patients. EA and Mox treatments both down-regu-
lated the abnormally increased SP and VIP expres-
sion in the colonic mucosa, with no significant dif-
ference shown between the two treatments.
CONCLUSION: Both EA and Mox treatments are ef-
fective at ameliorating gastrointestinal symptoms
by reducing SP and VIP expression in the colonic
mucosa of IBS patients.
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INTRODUCTION
Irritable bowel syndrome (IBS) is the most common
disorder presented to gastroenterologists, with a preva-
lence of up to 10%-20% in the UK and USA1,2 and a
prevalence of 5%-10% in most Asian countries.3,4 The
incidence of IBS increases with global economic
growth. The most common IBS presenting symptoms
are abdominal pain associated with altered bowel hab-
its (diarrhea or constipation). Although the exact mech-
anism of IBS gastrointestinal symptoms has not been
elucidated, visceral hypersensitivity and gastrointestinal
motility disorders are the main pathological causes.5
There is also evidence that IBS involves altered gut mo-
tility. Several brain-gut peptides, such as substance P
(SP) and vasoactive intestinal peptide (VIP), are in-
volved in the regulation of gastrointestinal motor and
sensory functions. SP and VIP are important brain-gut
peptides that are widely distributed in the central ner-
vous system, gastrointestinal tract, and immune or-
gans. These brain-gut peptides can affect gastrointesti-
nal movements through nervous, endocrine, immune,
and other means and may be involved in abdominal
pain or discomfort, abnormal defecation, and other vis-
ceral hypersensitivity reactions.6,7 Abnormal levels of SP
and/or VIP have been demonstrated in patients with
IBS with diarrhea (IBS-D) and IBS with constipation
(IBS-C).8
Sandler et al 9 revealed that abdominal pain was the
symptom most likely to result in IBS patients seeking a
medical consultation. The therapeutic options current-
ly available are limited and their lack of efficacy is of-
ten disappointing. In recent years, the stimulation of
certain acupoints or areas with electroacupuncture
(EA) or moxibustion (Mox) has appealed to some
scholars and a number of clinical10-14 and experimen-
tal15-19 studies have demonstrated its effectiveness, espe-
cially for curing abdominal pain or discomfort, abnor-
mal defecation, and other gastrointestinal symptoms in-
duced by visceral hypersensitivity. Our previous studies
found that SP and SP receptors expression were greater
in rats with IBS than in normal rats, indicating that SP
and SP receptors are closely related to the development
of IBS. EA at Zusanli (ST 36) and Shangjuxu (ST 37)
can decrease the number of mast cells and the expres-
sion of SP and SP receptors in the colon.19 In this
study, we investigated whether EA and/or Mox in
IBS-D and IBS-C patients affected abdominal pain or
discomfort, abnormal defecation and other gastrointes-
tinal symptoms, the expression of SP in the colonic
mucosa, and the expression of VIP. We compared dif-
ferences in curative capacity between the two therapies
in the hope of providing reliable evidence for the clini-
cal treatment of IBS-D and IBS-C.
MATERIALS ANDMETHODS
Participants
This research was approved by the Chinese Clinical Tri-
al Register Center (registration number: ChiC-
TR-TRC-11001349). All subjects were outpatients of
the Department of Gastroenterology in Jinhua Hospi-
tal of Zhejiang University from October 2011 to Sep-
tember 2012. All patients gave informed consent and
the trial was approved by the Ethics Committee of
Yueyang Chinese and Western Medicine Integrated
Hospital affiliated to Shanghai University of Tradition-
al Chinese Medicine.
We adopted a simple randomized design using the
SNOSE (sequentially numbered, opaque sealed enve-
lopes) method. We used a random number table and
the numbers generated were written on individual
cards and enclosed sequentially in envelopes. Then, the
order of each generated number was written on the en-
velopes and assigned to each eligible patient in order.
The random number on the enclosed cards determined
the group allocation for each patient: odd numbers de-
noted the EA group and even numbers denoted the
Mox group. The same randomization method was ap-
plied separately to IBS-D and IBS-C patients.
We assessed the eligibility of the initial 85 IBS patients
according to the Rome Ⅲ diagnostic criteria.20 Partici-
pants with intestinal organic diseases; combined heart,
liver, and kidney disease; mental illness; and pregnant
or lactating women with diarrhea were excluded . Of
the remaining patients, 43 patients aged 18 to 65 years
with IBS-D were randomly allocated to the EA treat-
ment group (n = 21) or the Mox treatment group (n =
22). Forty-two patients aged 18 to 65 years with IBS-C
were randomly allocated to the EA treatment group
(n = 21) or the Mox treatment group (n = 21). After
signing an informed consent form that was approved
by the ethics committee, all IBS-D and IBS-C patients
provided information about their main digestive tract
symptoms, including abdominal pain, abdominal dis-
tention, and diarrhea or constipation. 3 mm3 of sig-
moid or ileocecal mucosa (selected according to the ar-
ea in which the patient experienced abdominal pain or
discomfort) was removed via painless colonoscopy be-
fore and after treatment. Sigmoid mucosa was collected
from 10 healthy volunteers for comparison. The muco-
sa was placed in 10% formaldehyde solution for analy-
sis. All healthy volunteers were examined for enucleat-
ed colonic polyps and intestinal organic diseases and
had experienced no change in bowel habits or excre-
ment character.
Treatment methods
As patients entered the clinic, they were randomly allo-
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cated to a treatment group, as described above. For the
EA group, the acupoints Zusanli (ST 36) and
Shangjuxu (ST 37) were located using the national
GB-12346-90 acupoint standard. After the skin was
cleaned with a tincture of iodine and alcohol, sterile
acupuncture needles (0.30 mm in diameter, 40 mm
long, Hwatuo, Suzhou Medical Supplies Factory Co.,
Ltd., China) were inserted 20-25 mm into the skin. Af-
ter twisting and obtaining Qi (soreness, numbness, dis-
tension, and heaviness), each acupuncture needle was
connected to the electrical leads of the HANS Acu-
point Nerve Stimulator (Model LH 100A TENS, Nan-
jing Jisheng Medical Technology Co., Ltd., China) for
30 min, with a stimulation frequency of 2 Hz and a
stimulation intensity of 3.0 mA. The treatment was ap-
plied once per day, six times per week, for 4 consecu-
tive weeks.
For the Mox group, the acupoints Zusanli (ST 36) and
Shangjuxu (ST 37) were selected, and patients were
treated with warm moxibustion according to the fol-
lowing procedure. The lit moxa (2.5 cm in diameter,
Hwatuo, Suzhou Medical Supplies Factory Co., Ltd.,
China) was placed 1-2 cm above the acupoints and the
surface temperature of the acupoints was maintained at
(46 ± 1) ℃ for 30 min. The treatment was applied
once per day, six times per week, for 4 consecutive
weeks.
IBS gastrointestinal symptom scales
A Visual Analog Pain Scale21,22 was used to assess IBS-D
and IBS-C abdominal pain before and after treatment,
which ranged from 0 = none to 10 = severe. The Bris-
tol stool form scale23 was used to assess IBS-D and
IBS-C feces before and after treatment. This is a de-
scriptive, visual scale that comprises definitions and im-
ages of seven types of stool: Type 1: separate hard
lumps, like nuts (hard to pass). Type 2: sausage-shaped,
but lumpy. Type 3: like a sausage but with cracks on its
surface. Type 4: like an Italian sausage or snake,
smooth and soft. Type 5: soft blobs with clearcut edges
(passed easily). Type 6: fluffy pieces with ragged edges,
a mushy stool. Type 7: watery, no solid pieces, entirely
liquid. And the scores ranged from 1 (Type 1) to 7
(Type 7). For IBS-D patients, the scores 4 = none, 5 =
slight, 6 = moderate, and 7 = severe. However for
IBS-C patients, the scores 4 = none, 3 = slight, 2 =
moderate, and 1 = severe.
Immunohistochemistry
Immunohistochemical staining was used to detect SP
and VIP expressions in colon tissue. A sample of sig-
moid or ileocecal colon tissue fixed in 10% formalin
was embedded in paraffin, cut into 4-μm serial sections
and heated at 58 ℃ overnight. The sections were
washed in PHOSPHATE BUFFERED SALINE (PBS)
three times for 3 min. The sections were exposed to
0.01 M CITRATE BUFFER, pH 6.0, microwaved at
30% power for 20 min for heat fixation, and cooled to
room temperature. The sections were washed three
times with PBS for 3 min and exposed to 0.3% H2O2
for 20 min at room temperature to inhibit endogenous
peroxidases. Following a final PBS wash (3 × 3 min),
the samples were exposed to 20% normal goat serum
and incubated for 30 min. Antibodies were added
drop-wise (SP 1∶50, VIP 1∶200) and the sections were
incubated at 37 ℃ for 2 h. The sections were washed
with PBS three times for 3 min, incubated in HORSE-
RADISH PEROXIDASE/RABBIT reagent at 37 ℃
for 30 min and PBS-washed three times for 3 min.
The sections were then incubated in DIAMINOBEN-
ZIDINE chromogenic reagent for 8 to 12 min and
dyed with hematoxylin lining and blue in the presence
of hot water. After drying, the sections were wrapped
with neutral gum. A semi-quantitative analysis of the
staining was performed using the MIQAS medical im-
age quantitative analysis system (Shanghai Qiuwei Bio-
medical Technology Company, Shanghai, China). Posi-
tive results were indicated by the presence of brown or
tan particles in the stained colonic tissue cells. In each
slice, three positive areas were counted and assessed for
optical density (OD) in a high power field to calculate
an immunohistochemical positive index (IHC index =
positive area × OD / total area) for SP and VIP.
Statistical analysis
SPSS 16.0 statistical software (SPSS Inc., Chicago, IL,
USA) was used. For normally distributed variables, the
paired-sample t test was used to test differences within
the same group, and the two independent-samples t
test was used to test differences between the groups be-
fore and after treatment. Non-parametric tests were used
to analyze abnormally distributed variables; the Wilcox-
on signed-rank test was used to analyze within-group
differences and Wilcoxon rank sum test was used to
compare the differences between two groups. A P value
less than 0.05 was considered statistically significant.
RESULTS
Final study sample
Forty-two patients were randomly allocated to the EA
group (21 with IBS-D and 21 with IBS-C), among
which 38 patients completed all the treatment sessions
and were included in data analysis. Two IBS-D patients
withdraw halfway due to lack of therapeutic effect, one
IBS-C patient failed to finish the treatment sessions,
and one IBS-C patient withdrew for reasons unknown.
Forty-three patients (22 with IBS-D and 21 with
IBS-C) were randomly allocated to the Mox group, of
which all received the allocated treatment and were in-
cluded in data analysis (Figure 1).
Comparison of age and duration of
diarrhea-predominant and
constipation-predominant IBS
There were no significant differences in age (P =
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0.990, P > 0.05) or disease duration (P = 0.621, P >
0.05) between IBS-D patients in the EA and Mox
groups. There were no significant differences in age
(P = 0.430, P > 0.05) or disease duration (P = 0.552,
P > 0.05) between IBS-C patients in the EA and Mox
groups (Table 1).
Comparison of primary gastrointestinal symptoms in
diarrhea-predominant and
constipation-predominant IBS patients
Abdominal pain was assessed using the Visual Analog
Pain Scale. Stool form was assessed using the Bristol
Stool Form Scale.
There were no significant differences in abdominal
pain (P = 0.885, P > 0.05) or stool form (P = 0.679, P >
0.05) between IBS-D patients in the EA andMox groups
before treatment. There were no significant differences
in abdominal pain (P = 0.825, P > 0.05) or stool form
(P = 0.815, P > 0.05) between IBS-C patients in the
EA and Mox groups before treatment (Table 2).
IBS-D and IBS-C patients in both the EA and Mox
groups experienced a significant improvement in ab-
dominal pain after treatment (all P < 0.001), with no
difference between the two groups (P = 0.361, P =
0.861, all P > 0.05). In the IBS-D patients, the EA
group experienced a significant improvement in stool
features (P = 0.009, P < 0.01) after treatment, whereas
the Mox group experienced a very significant improve-
ment in stool features (P < 0.001), with the Mox
group feeling significantly better than the EA group af-
ter treatment (P < 0.001). In the IBS-C patients, the
EA group experienced a significant improvement in
stool features (P < 0.001) after treatment, whereas the
Mox group experienced no significant difference be-
fore and after treatment (P = 0.065, P > 0.05), with
the EA group feeling significantly better than the
Mox group after treatment (P < 0.001) (Table 2).
These findings suggest that both EA and Mox are ef-
fective at treating IBS-D and IBS-C patients with ab-
dominal pain, which is the main symptom of diges-
tive tract problems. However, Mox is better than EA
at improving stool features in IBS-D patients, but
EA is better than Mox at improving stool features in
IBS-C patients.
Comparison of colonic mucosa SP expression in
diarrhea-predominant and
constipation-predominant IBS patients
SP in each group was mainly expressed in the basal por-
tion of the colonic mucosa, lamina propria, and muscu-
lar plexus before treatment, with a strong brown reac-
tion in staining and a scattered, knot-like, or clustered
distribution (Figure 2).
Group
IBS-D EA
IBS-D Mox
IBS-C EA
IBS-C Mox
n
19
22
19
21
Age (years)
39±5
39±8
40±12
42±8
Disease duration (years)
5±4
4±4
6±4
7±5
Table 1 Baseline characteristics ( xˉ ± s)
Notes: EA and Mox groups received electroacupuncture or
warm moxibustion treatment on Zusanli (ST 36) and
Shangjuxu (ST 37) once a day for 14 consecutive days. IBS-D:
irritable bowel syndrome with diarrhea; IBS-C: irritable bowel
syndrome with constipation; EA: electroacupuncture group;
Mox: moxibustion group.
Assessed for eligibility (n = 90)
Excluded (n = 5)
Not meeting inclusion criteria (n = 2)
Declined to participate (n = 2)
Other reasons (n = 1)
Randomized (n = 85)
Allocated to EA group (n = 42)
Received allocated intervention (n = 38)
Did not receive allocated intervention
(n = 4)
(no therapeutic effect = 2; withdraw = 2)
Allocated to Mox group (n = 43)
Received allocated intervention (n = 43)
Did not receive allocated intervention (n = 0)
Analysed (n = 38)
IBS-D (n = 19) IBS-C (n = 19)
Analysed (n = 43)
IBS-D (n = 22) IBS-C (n = 21)
Figure 1: flow diagram of the study.
IBS-D: Irritable bowel syndrome with diarrhea; IBS-C: Irritable bowel syndrome with constipation; EA: electro-acupuncture group;
Mox: moxibustion group.
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Before treatment, SP expression in the colonic mucosa
was significantly higher in IBS-D and IBS-C patients
in both the EA and Mox groups compared with
healthy volunteers (all P < 0.001). Furthermore, there
were no significant differences in expression between
the EA and Mox groups for either IBS-D or IBS-C pa-
tients (P = 0.138, P = 0.940, both P > 0.05) (Table 3).
In comparison, after treatment, SP expression in the co-
lonic mucosa was significantly reduced for IBS-D and
IBS-C patients in both the EA and Mox groups (all P <
Figure 2 Comparison of SP expression within IBS-D and IBS-C patients before and after EA or Mox treatment
EA and Mox groups received electro-acupuncture or warm moxibustion treatment on ST-36 and ST-37 for once a day for 14 con-
secutive days. A-I: SP expressions in colonic mucosa were dyed by immunohistochemical staining method (×200). A-B: SP expres-
sion of IBS-D patients before and after EA treatment; C-D: SP expression of IBS-D patients before and after Mox treatment; E-F: SP
expression of IBS-C patients before and after EA treatment; G-H: SP expression of IBS-D patients before and after Mox treatment; I:
SP expression of normal control. IBS-D: Irritable bowel syndrome with diarrhea; IBS-C: Irritable bowel syndrome with constipation;
EA: electro-acupuncture group; Mox: moxibustion group; SP: substance P.
IG H
A B C
D E F
Symptom
Abdominal pain
Stool form
Group
IBS-D EA
IBS-D Mox
IBS-C EA
IBS-C Mox
IBS-D EA
IBS-D Mox
IBS-C EA
IBS-C Mox
n
19
22
19
21
19
22
19
21
Before treatment
6.4±1.5
6.4±1.0
4.0±1.9
3.9±1.9
6.4±0.5
6.5±0.6
1.4±0.8
1.5±0.7
After treatment
2.7±1.3a
2.3±1.6a
1.5±1.2a
1.6±1.3a
5.9±0.7c
4.7±0.6ab
3.3±0.6a
1.9±0.9b
Table 2 Comparison of therapeutic effects in IBS-D and IBS-C patients in the EA and Mox groups before and after treatment ( xˉ ± s)
Notes: abdominal pain was rated using the visual analog pain scale; stool form was recorded using the bristol stool form scale. EA and Mox
groups received electroacupuncture or warm moxibustion treatment on Zusanli (ST 36) and Shangjuxu (ST 37) once a day for 14 consecu-
tive days. IBS-D: irritable bowel syndrome with diarrhea; IBS-C: irritable bowel syndrome with constipation; EA: electroacupuncture
group; Mox: moxibustion group. aP < 0.001, compared with the data before treatment in the same group; bP < 0.001, compared with the
data from the EA group; cP < 0.01, compared with the data before treatment in the same group.
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0.001). There was no significant difference between the
EA and Mox groups for IBS-D patients (P = 0.876, P >
0.05), but there was a significant difference between the
EA and Mox groups for IBS-C patients (P = 0.024, P <
0.05), indicating that EA was more effective in reducing
over-expressed SP in the colonicmucosa (Table 4).
Comparison of colonic mucosa VIP expression in
diarrhea-predominant and
constipation-predominant IBS patients
Before treatment, VIP in each group was mainly ex-
pressed in the colonic mucosa, submucosal plexus, and
myenteric plexus, with a strong brown reaction in stain-
ing thatwas scattered or linear in distribution (Figure 3).
Before treatment, the expression of VIP in the colonic
mucosa was significantly higher in IBS-D and IBS-C
patients of both the EA and Mox groups compared
with healthy volunteers (all P < 0.001). Furthermore,
there was no significant difference between the EA and
Mox groups for either IBS-D or IBS-C patients (P =
0.779, P = 0.971, both P > 0.05) (Table 3).
In comparison, after treatment, significant reductions
in VIP expression in the colonic mucosa were observed
for IBS-D and IBS-C patients in both the EA and Mox
groups (all P < 0.001). There was no significant differ-
ence between the EA and Mox groups for IBS-D pa-
tients (P = 0.142, P > 0.05), but there was a significant
difference between the EA and Mox groups for IBS-C
patients (P < 0.001), indicating that EA was more ef-
fective at reducing over-expressed VIP in the colonic
mucosa (Table 4).
DISCUSSION
IBS is a functional bowel disorder that is characterized
by abdominal pain or discomfort and disturbed bowel
habits. IBS pathogenesis involves many factors, such as
abnormal gastrointestinal motility, visceral hypersensi-
tivity, inflammation, and brain-gut axis and psychologi-
cal abnormalities. Recommended treatments range
from patient education, cognitive therapy, dietary mod-
ifications, and antispasmodics to psychological mea-
sures, including hypnotherapy, behavioral therapy, and
newly developed neuropeptide receptor agonists and
antagonists.4 The clinical applications of Western Medi-
cine are hindered by adverse effects from long-term or
repeated use of medications as well as huge economic
costs. In recent years, clinical studies have demonstrat-
ed the curative effects of acupuncture and Mox for
IBS. Under stress, various physiological and psychologi-
cal stimuli can cause changes in gastrointestinal motili-
ty. These can be regulated by acupuncture and Mox,
which can (individually and in combination) positively
adjust physiological and psychological systems, thereby
alleviating clinical symptoms.10-14 Acupuncture and
Mox can also improve the visceral hypersensitivity that
is characteristic of IBS.15-19
Autonomic dysfunction is common in IBS patients.
IBS-D patients suffer from hyperactivity of the colon
and rectum, manifesting an increased activity of the va-
gus (parasympathetic) nerve and decreased activity of
the sympathetic nerve. SP and VIP, located in the enter-
ic nervous system, are involved in the regulation of gas-
trointestinal motility and visceral hypersensitivity.6-7 SP
has a strong stimulating effect on gastrointestinal
smooth muscle. In combination with a variety of SP re-
Group
IBS-D EA
IBS-D Mox
IBS-C EA
IBS-C Mox
NC
n
19
22
19
21
10
SP
139±46a
162±49a
132±29a
131±32a
61±8
VIP
135±41a
139±45a
152±39a
152±40a
63±9
Table 3 Comparison of SP and VIP expression before treat-
ment between IBS-D and IBS-C patients and the normal con-
trol group ( xˉ ± s)
Notes: EA and Mox groups received electroacupuncture or
warm moxibustion treatment on Zusanli (ST 36) and
Shangjuxu (ST 37) once a day for 14 consecutive days. SP: sub-
stance P; VIP: vasoactive intestinal peptide; IBS-D: irritable
bowel syndrome with diarrhea; IBS-C: irritable bowel syndrome
with constipation; EA: electroacupuncture group; Mox: moxi-
bustion group; NC: normal control group. aP < 0.001 compared
with the normal control group.
Group
IBS-D EA
IBS-D Mox
IBS-C EA
IBS-C Mox
n
19
22
19
21
SP
Before treatment
139±46
162±49
132±29
131±32
After treatment
100±37a
102±32a
84±14a
100±25ab
VIP
Before treatment
135±41
139±45
152±39
152±40
After treatment
100±23c
89±20c
103±26c
140±32cd
Notes: EA and Mox groups received electroacupuncture or warm moxibustion treatment on Zusanli (ST 36) and Shangjuxu (ST 37) once
a day for 14 consecutive days. SP: substance P; VIP: vasoactive intestinal peptide; IBS-D: irritable bowel syndrome with diarrhea; IBS-C:
irritable bowel syndrome with constipation; EA: electroacupuncture group; Mox: moxibustion group. aP < 0.001 compared with data be-
fore treatment in the same group; bP < 0.05 compared with the IBS-C EA group after treatment; cP < 0.001 compared with data before
treatment in the same group; dP < 0.001 compared with the IBS-C EA group after treatment.
Table 4 Comparison of SP and VIP expression before and after treatment in IBS-D and IBS-C patients ( xˉ ± s)
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ceptors in target cells, it causes high intestinal sensitivi-
ty (hyperalgesia) and intestinal motility disorders and
induces IBS. Furthermore, SP can increase vascular per-
meability and promote the secretion of intestinal muco-
sal secretory cells.24,25 VIP, an inhibitory neurotransmit-
ter, enacts an inhibitory regulation on gastrointestinal
motility. It can promote vasodilation, relaxation of the
gastrointestinal smooth muscles, reduction of visceral
resistance, regulation of intestinal sodium metabolism,
and the release of certain enzymes and hormones.26-28
Yao et al 29 found a significantly reduced abdominal
contraction threshold in rats with visceral hypersensitiv-
ity and enhanced intestinal motility, which were relat-
ed to SP and the significantly enhanced expression of
its receptors (mainly neurokinin type 1 receptors) in
the intestinal mucosa and muscle layer. Valero et al 30
found that the combination of SP and the neurokinin
type 1 receptors directly causes small intestine smooth
muscle contractions in rabbits, suggesting that SP may
increase visceral sensitivity and accelerate gastrointesti-
nal motility. Deng et al 31 found that small intravenous
doses of SP in healthy rats can excite the subdiaphrag-
matic vagus nerve and enhance gastrointestinal motili-
ty, whereas large injection doses of SP enact an inhibi-
tory effect on gastrointestinal motility, supporting the
theory that SP affects gastrointestinal motility. Zhao et
al 32 observed that VIP in the plasma of patients after
abdominal surgery, and before the recovery of gastroin-
testinal function, was significantly higher than after the
recovery of gastrointestinal function. They also found
that VIP expression in the myenteric plexus in chronic
constipation-predominant rats was higher than in
healthy rats. Keller et al 33 reported that intravenous
VIP injection in healthy individuals caused the secre-
tion of intestinal sodium and increased water and diar-
rhea. They also found that VIP can both inhibit peri-
stalsis and promote the secretion of water and electro-
lytes in the intestinal mucosa. Lan et al 34 demonstrated
that both SP and VIP can promote intestinal mucosal
mast cell degranulation and the release of histamine,
leading to increased capillary permeability, glandular se-
cretion, and other biological effects. In the present
study, we found that SP and VIP in the colonic muco-
sa were significantly greater in both IBS-D and IBS-C
patients than in healthy volunteers, indicating that
these abnormally increased neurotransmitters may af-
IG H
A B C
D E F
Figure 3 Comparison of VIP expression within IBS-D and IBS-C patients before and after EA or Mox treatment
EA and Mox groups received electro-acupuncture or warm moxibustion treatment on Zusanli (ST 36) and Shangjuxu (ST 37) for
once a day for 14 consecutive days. A-I: VIP expressions in colonic mucosa were dyed by immunohistochemical staining method
(×200). A-B: VIP expression of IBS-D patients before and after EA treatment; C-D: VIP expression of IBS-D patients before and after
Mox treatment; E-F: VIP expression of IBS-C patients before and after EA treatment; G-H: VIP expression of IBS-D patients before
and after Mox treatment; I: VIP expression of normal control. IBS-D: irritable bowel syndrome with diarrhea; IBS-C: irritable bowel
syndrome with constipation; EA: electro-acupuncture group; Mox: moxibustion group; VIP: vasoactive intestine peptide.
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fect intestinal motility and mucosal secretion and in-
crease visceral hypersensitivity through nervous, endo-
crine, or immune means. These effects can cause ab-
dominal pain or discomfort, diarrhea, constipation,
and other gastrointestinal symptoms in IBS-D and
IBS-C patients. These results indicate that SP and VIP
in the colonic mucosa are involved in the visceral hy-
peractivity and intestinal disorder mechanisms of IBS.
Our research group previously found that EA on Zu-
sanli (ST 36) and Shangjuxu (ST 37) in IBS model
rats can significantly inhibit SP in the colonic mucosa
and VIP expression.19,35 In the present study, Zusanli
(ST 36) and Shangjuxu (ST 37) were selected to deter-
mine whether there were any curative differences be-
tween EA and Mox in IBS-D and IBS-C patients.
Both IBS-D and IBS-C patients demonstrated signifi-
cantly reduced SP in the colonic mucosa and reduced
VIP expression compared with before the treatment,
and their abdominal pain symptoms were significantly
alleviated. However, we found that Mox was signifi-
cantly better than EA at improving thin or watery
stools in IBS-D patients, whereas EA was significantly
better than Mox at improving unsmooth or dry stools,
reducing SP in the colonic mucosa, and reducing the
expression of VIP in IBS-C patients.
In conclusion, this study suggests that either EA or
Mox are effective clinical treatments for IBS patients
suffering from abdominal pain. However, we recom-
mend that IBS-D patients should choose Mox, and
IBS-C patients choose EA, for optimal curative effects.
Furthermore, we lost four IBS patients who received
EA treatment throughout the whole study. Of which
two IBS-D patients withdraw halfway due to lack of
therapeutic effect, and the optimal choice of EA and
MOX when treated IBS patients with different master
gastrointestinal disorders (diarrhea or constipation)
maybe the main reason. We will improve the research
design in the future.
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